The South America tulathromycin market size has witnessed significant growth in the past and is expected to grow at a CAGR of 3.3% during the forecast period (2022–2031). An antibiotic called tulathromycin treats respiratory diseases in dairy cattle and swine. Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin.
The high prevalence of BRD and SRD drives the South American tulathromycin market. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin is an opportunity for the tulathromycin market.
BRD is the most common pathology in young and adult animals, affecting 20–25% of calves annually, 10% of which experience growth retardation and up to 6% die. Swine can also have an SRD prevalence rate of around 20%, with a mortality rate of up to 20% and a risk of sequelae in up to 40% of affected animals. Beyond the effects on animal health, BRD and SRD have a significant financial impact on the farmer because of the reduction in animal growth, the expense of diagnosis and treatment, mortality, and the cost of additional work.
Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects Swines and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
Given the increasing attention paid to animal welfare, the Asia Pacific tulathromycin market has a sizable opportunity. Consumers are looking for products that reflect their ideals and give the ethical treatment of animals more weight. In the veterinary pharmaceutical industry, where customers are looking for antibiotics and other treatments that improve animals’ general health and well-being, this shift in consumer preferences is also present.
For the tulathromycin market, highlighting the antibiotic's role in improving animal health and welfare can help companies stand out and attract conscious consumers. Tulathromycin is a powerful antibiotic that can treat and prevent bacterial and respiratory infections in animals, which is essential for maintaining animal health and reducing suffering.
Additionally, businesses can participate in transparent and traceable supply chains, disclosing where tulathromycin is sourced and guaranteeing its manufacture complies with stringent animal welfare requirements. This may entail collaborating closely with livestock farmers to ensure cattle are raised in conditions that support their well-being, such as having access to enough space, wholesome food, and veterinary treatment. By exhibiting these initiatives, companies can attract customers who are concerned about the conditions in which animals are raised and look for products that contribute to their well-being.
| Study Period | 2020-2032 | CAGR | 3.3% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD XX Billion |
The South American tulathromycin market is segmented based on the country into Brazil. Brazil dominates the country market and is expected to grow at a CAGR of 3.6% during the forecast period.
The main economies in South America with the highest populations of cattle and pigs are Brazil, Mexico, Argentina, and Colombia. According to our research, Brazil is home to more than 51% of the world's cattle. Additionally, the region is home to more than 29% of the world's cattle, contributing to 29% of global beef production. Brazil has seen a sharp rise in the total number of cattle in recent years as the nation has begun to export more beef. However, compared to North America, South America has a far lower prevalence of BRD.
As of 2020, South America has over 4 million pigs. The number keeps increasing as more people in the area start eating pork. For treating SRD, tulathromycin is anticipated to have higher growth prospects as the number of pigs in the area rises. In some of the largest pork-producing countries in South America, the prevalence of SRD is notably high.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The South American tulathromycin market is segmented based on animal and country.
Based on animals, the market is segmented into cattle and swine.
Cattle dominates the market and is expected to register a CAGR of 3.7% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.
